# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce SALL4 and its role
- limitations of peptide-based therapies
- need for improved peptide-based drugs

## SUMMARY OF THE INVENTION

- introduce isolated peptides targeting SALL4-RBBp4 interaction
- describe therapeutic value of isolated peptides
- describe pharmaceutical compositions
- describe method of inhibiting SALL4-RBBp4 binding
- describe methods of treating disorders

## DETAILED DESCRIPTION OF THE INVENTION

### Isolated Peptides and Compositions Comprising Isolated Peptides

- introduce isolated peptides
- define peptide
- introduce formula (I)
- explain amino acid sequence convention
- define non-polar side chain
- define polar side chain that is not charged at neutral pH
- define polar side chain that is charged at neutral pH
- explain substantially charged
- specify embodiments of X1-X7
- introduce optional amino acids
- exclude WT SALL4 peptide
- define unnatural amino acid
- introduce formula (Ia)
- define isolated peptides
- describe formula (Ia)
- specify amino acids X0-X7
- provide isolated peptides with optional amino acids
- introduce formula (II)
- describe "A" in formula (II)
- list N-terminal protecting groups
- describe "B" in formula (II)
- list C-terminal protecting groups
- specify first embodiment of peptides
- specify second embodiment of peptides
- specify third embodiment of peptides
- specify fourth embodiment of peptides
- specify fifth embodiment of peptides
- specify sixth embodiment of peptides
- specify seventh embodiment of peptides
- specify eighth embodiment of peptides
- specify ninth embodiment of peptides
- specify tenth embodiment of peptides
- list additional peptide sequences
- list additional peptide sequences
- list additional peptide sequences
- list additional peptide sequences
- list additional peptide sequences
- list additional peptide sequences
- list additional peptide sequences
- list additional peptide sequences
- describe isolated peptides and compositions
- protect terminal ends of peptides
- introduce cell-penetrating peptides
- define cell-penetrating peptides
- describe covalent linking of peptides
- provide isolated peptides that bind to RBBp4 protein
- define binding affinity
- describe measurement of binding affinity
- provide isolated peptides with high binding affinity
- describe IC50 values of isolated peptides
- describe KD values of isolated peptides
- provide isolated peptides that inhibit RBBp4 activity
- provide isolated peptides that inhibit SALL4 expression
- provide isolated peptides that inhibit SALL4 functional activity
- provide isolated peptides that inhibit downstream signaling of SALL4
- provide isolated peptides that promote PTEN expression
- provide isolated peptides that promote PTEN functional activity
- describe length of isolated peptides
- define SALL4
- define RBBp4
- describe applications of isolated peptides
- provide pharmaceutical compositions comprising isolated peptides
- describe covalent linking of isolated peptides to cell-penetrating peptides
- provide pharmaceutical compositions with specific isolated peptides
- describe formulation of pharmaceutical compositions
- describe excipients and carriers for pharmaceutical compositions
- describe dosage forms of pharmaceutical compositions
- describe modes of administration of pharmaceutical compositions

### Methods of Inhibition and Treatment

- introduce SALL4 functions
- describe SALL4 down-regulation in adult tissues
- explain SALL4 re-activation in disease states
- discuss SALL4-induced tumorigenesis
- describe SALL4-NuRD interaction
- introduce isolated peptides for disrupting SALL-NuRD interaction
- define method for inhibiting SALL4-RBBp4 binding
- explain inhibiting SALL4 activity or expression
- describe contacting cell with isolated peptide
- define "cell" as used in the invention
- explain high levels of SALL4
- describe method for inhibiting SALL4-RBBp4 binding in malignant cells
- explain reducing proliferation of malignant cells
- introduce method for treating disorder mediated by SALL4 dysregulation
- define "dysregulation" of SALL4
- describe administering pharmaceutical composition
- define "pharmaceutical composition"
- explain using functionally equivalent homologues or analogues
- describe method for treating subject having disorder mediated by SALL4 dysregulation
- define "method" as used in the invention
- explain treating a medical condition
- define "disorder" as used in the invention
- describe subject as vertebrate or mammal
- explain administering pharmaceutical composition as prophylactic or therapeutic
- describe suitable dosage forms
- explain therapeutically effective amount
- introduce method for treating cancer
- describe administering pharmaceutical composition to subject having cancer
- explain treating solid tumors expressing SALL4

### Exemplification

- introduce SALL4 binding to RBBp4 of NuRD
- confirm direct binding using isothermal titration calorimetry
- confirm binding kinetics using surface plasmon resonance
- determine crystal structure of RBBp4-SALL4 complex
- describe RBBp4 structure and SALL4 binding site
- identify key interactions between SALL4 and RBBp4 residues
- summarize key interactions in Table 2
- perform computational analysis of RBBp4-SALL4 interaction
- identify essential residues for RBBp4-SALL4 interaction
- perform biochemical alanine scan of essential residues
- analyze effect of mutations on binding free energy
- perform cell viability assay with mutant peptide
- analyze effect of mutant peptide on PTEN expression
- optimize candidate therapeutic peptide
- determine minimum length of peptide required for bioactivity
- perform truncation analysis of WT peptide
- analyze effect of C-terminal truncations on binding affinity
- perform systematic single-residue mutation analysis
- identify non-essential residues for sequence optimization
- analyze effect of substitutions on binding affinity
- incorporate substitutions into optimized peptide FFW
- analyze therapeutic effect of FFW in vitro
- analyze therapeutic effect of FFW in vivo
- compare efficacy of FFW with WT and MUT peptides
- analyze specificity of FFW in targeting SALL4-high HCC cells
- study therapeutic effect of PEN-FFW in vivo
- analyze drug-like properties of PEN-FFW
- study toxicity of PEN-FFW in vivo

### Materials and Methods

- describe ITC assay
- perform ITC experiment
- analyze ITC data
- describe SPR study
- perform SPR experiment
- analyze SPR data
- describe FP assay
- perform FP experiment
- analyze FP data
- describe crystallization method
- perform crystallization experiment
- determine crystal structure
- describe computational alanine scanning
- perform CAS calculation
- analyze CAS results
- describe cell culture and treatment
- perform cell culture experiment
- describe xenograft study
- perform xenograft experiment
- analyze xenograft data

